Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Helixmith Co., Ltd is a biotechnology enterprise focused on discovering and advancing novel biopharmaceutical solutions for human diseases. The company maintains a comprehensive pipeline of innovative biologics and herbal therapies, addressing therapeutic areas like cardiovascular ailments, cancer, and immune system disorders. Its clinical research activities are actively conducted across the United States, South Korea, and China. A cornerstone of its product portfolio is VM202, a groundbreaking DNA-based drug designed for treating both cardiovascular and neurological conditions. Additionally, Helixmith's developmental compounds include VM206, a therapeutic vaccine targeting HER2/neu positive breast or ovarian cancer, and VM501, a re-engineered variant of interleukin 11 aimed at alleviating chemotherapy-induced thrombocytopenia. Its ongoing clinical trials encompass VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. Founded in 1996, the company adopted the name Helixmith Co., Ltd in April 2019, transitioning from its former identity as ViroMed Co., Ltd. The organization's main office is located in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.